Health officials in the United States recently revealed the price tag of Remdesivir
Health officials in the United States on Monday revealed the price tag of Remdesivir, the first COVID-19 antiviral drug, and will be distributed under an “unusual agreement” with the federal government.
The said agreement would establish non-negotiable prices and would prioritize patients in the United States.
Ernst Berndt, a retired health economist at the Massachusetts Institute of Technology Sloan School of Management, mentioned that the said arrangement might serve as a template for the distribution of new vaccines and treatments as the COVID-19 pandemic swell.
According to the Department of Health and Human Services (HHS) and Gilead Sciences, Remdesivir will be sold to hospitals for the treatment of patients with private insurance for the price USD 520 for every vial or USD 3,120 for every treatment course.
In addition, the price of Remdesivir will be sold to patients on government-sponsored insurance and to those in other countries with national health care systems for the price of USD 390 for every vial or USD 2,340 for every treatment course.
- US FDA Approves Remdesivir, Issues Emergency-use Authorization
- Gilead Sciences Exporting Remdesivir, To Donate 1.5 Million Vials — CEO
- Remdesivir Still Part Of Ongoing Clinical Trial In PH, Says DOH
In a report on ABS-CBN News, Remdesivir will only be sold in the United States through September, which means, patients in the United States will receive almost the entirety of Gilead Science’s output with over 500,000 treatment courses.
The Department of Health and Human Services and state health departments had been allocating Remdesivir to hospitals nationwide based on need. They would no longer have a role in determining where Remdesivir was sent after September.
Gilead Sciences was the manufacturer of Remdesivir.
What can you say about the price tag of Remdesivir? Let us know!